The Mannose/N-Acetylgalactosamine-4-SO4Receptor Displays Greater Specificity for Multivalent than Monovalent Ligands

Daniel S. Roseman, Jacques Baenziger

Journal of Biological Chemistry · 2001 · 34 citations · 23 references

DOIFull text

Open access

Concepts

Abstract

Recognition of carbohydrates on glycosylated molecules typically requires multivalent interactions with receptors. Monovalent forms of terminal saccharides engaged by the receptor binding sites typically display weak affinities in the mm range and poor specificity. In contrast, multivalent forms of the same saccharides are bound with strong affinity (10−7–10−9m) and significantly greater specificity. Although multivalency can readily account for increased affinity, the molecular basis for enhanced specificity is not well understood. We have examined the specificity of the cysteine-rich domain of the mannose/GalNAc-4-SO4receptor using monovalent and multivalent forms of the trisaccharide GalNAcβ1,4GlcNAcβ1,2Manα (GGnM) sulfated at either the C4 (S4GGnM) or C3 (S3GGnM) hydroxyl of the terminal GalNAc. Monovalent S4GGnM and S3GGnM have Ki values of 25.8 and 16.2 μm, respectively. Multivalent conjugates of the same GalNAc-4-SO4- and GalNAc-3-SO4-bearing trisaccharides (6.7 mol of trisaccharide/mol of bovine serum albumin) have Ki values of 0.013 and 0.170 μm, respectively. The 2000-fold versus 95-fold change in affinity seen for the multivalent forms of these 4-sulfated and 3-sulfated trisaccharides reflects a difference in the impact of conformational entropy. A large fraction of the SO4-3-GalNAc structures exists in a form that is not favorable for binding to the Cys-rich domain. This reduces the effective concentration of SO4-3-GalNAc as compared with SO4-4-GalNAc under the same conditions and results in a markedly lower association rate. This difference in association rate accounts for the 12-fold difference in the rate of clearance from the blood seen with S4GGnM-BSA and S3GGnM-BSA in vivo. Recognition of carbohydrates on glycosylated molecules typically requires multivalent interactions with receptors. Monovalent forms of terminal saccharides engaged by the receptor binding sites typically display weak affinities in the mm range and poor specificity. In contrast, multivalent forms of the same saccharides are bound with strong affinity (10−7–10−9m) and significantly greater specificity. Although multivalency can readily account for increased affinity, the molecular basis for enhanced specificity is not well understood. We have examined the specificity of the cysteine-rich domain of the mannose/GalNAc-4-SO4receptor using monovalent and multivalent forms of the trisaccharide GalNAcβ1,4GlcNAcβ1,2Manα (GGnM) sulfated at either the C4 (S4GGnM) or C3 (S3GGnM) hydroxyl of the terminal GalNAc. Monovalent S4GGnM and S3GGnM have Ki values of 25.8 and 16.2 μm, respectively. Multivalent conjugates of the same GalNAc-4-SO4- and GalNAc-3-SO4-bearing trisaccharides (6.7 mol of trisaccharide/mol of bovine serum albumin) have Ki values of 0.013 and 0.170 μm, respectively. The 2000-fold versus 95-fold change in affinity seen for the multivalent forms of these 4-sulfated and 3-sulfated trisaccharides reflects a difference in the impact of conformational entropy. A large fraction of the SO4-3-GalNAc structures exists in a form that is not favorable for binding to the Cys-rich domain. This reduces the effective concentration of SO4-3-GalNAc as compared with SO4-4-GalNAc under the same conditions and results in a markedly lower association rate. This difference in association rate accounts for the 12-fold difference in the rate of clearance from the blood seen with S4GGnM-BSA and S3GGnM-BSA in vivo. lutropin mannose SO4-4-GalNAcβ1,4GlcNAcβ1,2Manα SO4-3-GalNAcβ1,4GlcNAcβ1,2Manα bovine serum albumin O-(CH2)8OOCH3 3′-O-SO3Galβ1,4(Fucα1,3)GlcNAc Man/GalNAc-4-SO4-Fc(Mu0), transmembrane and cytosolic domains of Man/GalNAc-4-SO4 receptor replaced with the Fc refion of human IgG1 Man/GalNAc-4-SO4Fc(Mu10), fibronectin type II repeat and carbohydrate recognition domains 1–3 deleted from Man/GalNAc-4-SO4Fc(Mu0) Man/GalNAc-4-SO4-Fc(Mu11), fibronectin type II repeat and carbohydrate recognition domains 1–8 deleted from Man/GalNAc-4-SO4-Fc(Mu0) surface plasmon resonance 9-aminopyrene-1,4,6-trisulfonic acid 3-[N-morpholino]propane sulfonic acid We previously demonstrated that glycoproteins such as LH1 and thyrotropin bearing N-linked oligosaccharides terminating with β1,4-linked GalNAc-4-SO4 are recognized by a receptor located in hepatic endothelial cells, the Man/GalNAc-4-SO4receptor, and are rapidly removed from the circulation (1Baenziger J.U. Kumar S. Brodbeck R.M. Smith P.L. Beranek M.C. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 334-338Crossref PubMed Scopus (160) Google Scholar, 2Fiete D. Srivastava V. Hindsgaul O. Baenziger J.U. Cell. 1991; 67: 1103-1110Abstract Full Text PDF PubMed Scopus (264) Google Scholar, 3Fiete D. Baenziger J.U. J. Biol. Chem. 1997; 272: 14629-14637Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar, 4Fiete D. Beranek M.C. Baenziger J.U. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 11256-11261Crossref PubMed Scopus (76) Google Scholar). Rapid clearance in conjunction with stimulated release from dense core storage granules in LH-producing cells located in the anterior lobe of the pituitary produce the episodic rise and fall in serum LH levels that is important for the expression of LH bioactivity in vivo. A novel feature of the Man/GalNAc-4-SO4 receptor is its capacity to bind carbohydrate moieties terminating with Man and GalNAc-4-SO4 at physically distinct domains that are not structurally related. The binding site for GalNAc-4-SO4 is located in the cysteine-rich domain found at the N terminus of the Man/GalNAc-4-SO4 receptor (5Fiete D.J. Beranek M.C. Baenziger J.U. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 2089-2093Crossref PubMed Scopus (154) Google Scholar). The Cys-rich domain is a member of the β-trefoil family of proteins that includes proteins such as acidic fibroblast growth factor. The binding site is a neutral pocket that accommodates the sulfate group, which accounts for the major interactions with the protein (6Liu Y. Chirino A.J. Leteux C. Feizi T. Misulovin Z. Nussenzweig M.C. Bjorkman P. J. Exp. Med. 2000; 191: 1105-1115Crossref PubMed Scopus (113) Google Scholar). Inhibition and modeling studies with monovalent ligands have indicated that the binding site in the Cys-rich domain can also accommodate saccharides with terminal Gal or GalNAc when the sulfate is located at C3 rather than C4 (6Liu Y. Chirino A.J. Leteux C. Feizi T. Misulovin Z. Nussenzweig M.C. Bjorkman P. J. Exp. Med. 2000; 191: 1105-1115Crossref PubMed Scopus (113) Google Scholar, 7Leteux C. Chai W. Loveless R.W. Yuen C.-T. Uhlin-Hansen L. Combarnous Y. Jankovic M. Maric S.C. Misulovin Z. Nussenzweig M.C. Feizi T. J. Exp. Med. 2000; 191: 1117-1126Crossref PubMed Scopus (149) Google Scholar). The latter observations were unexpected because we had reported that bovine serum albumin substituted with 6–8 molecules of SO4-4-GalNAcβ1,4GlcNAcβ1,2Manα (S4GGnM-BSA) is removed from the circulation at a rate that is at least 12-fold greater than that seen for bovine serum albumin substituted with 6–8 molecules of SO4-3-GalNAcβ1,4GlcNAcβ1,2Manα (S3GGnM-BSA). Furthermore, isolated hepatic endothelial cells do not bind and internalize S3GGnM-BSA, and the purified Man/GalNAc-4-SO4receptor does not display significant binding of S3GGnM-BSA in precipitation assays (2Fiete D. Srivastava V. Hindsgaul O. Baenziger J.U. Cell. 1991; 67: 1103-1110Abstract Full Text PDF PubMed Scopus (264) Google Scholar, 3Fiete D. Baenziger J.U. J. Biol. Chem. 1997; 272: 14629-14637Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar). We have recently determined that the Man/GalNAc-4-SO4 receptor must be dimeric and engage at least two terminal GalNAc-4-SO4 moieties on separate oligosaccharides to mediate uptake by hepatic endothelial cells with aKd of 1.63 × 10−7m(8Roseman D.S. Baenziger J.U. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 9949-9954Crossref PubMed Scopus (68) Google Scholar). These observations raise the possibility that the Man/GalNAc-4-SO4 receptor may display significantly greater specificity when binding ligands with multiple terminal sulfated saccharide moieties than when binding monovalent forms of the same ligands. We have examined this possibility using well characterized ligands of known valency and structure. Our studies demonstrate that the Man/GalNAc-4-SO4 receptor displays greater specificity for multivalent forms of the same structures than for monovalent forms and that this can be explained best by the presence of favorable and unfavorable conformations of the trisaccharides for binding to the Cys-rich domain. Remarkably, inhibition constants obtained with the monovalent forms of these trisaccharides are not predictive of the properties of multivalent forms of the same structures. Man/GalNAc-4-SO4-Fc(Mu0) (the transmembrane and cytosolic domains are replaced by the hinge, CH2, and CH3 domains of human IgG1), Man/GalNAc-4-SO4-Fc(Mu10) (deletion of the fibronectin type II repeat and carbohydrate recognition domains (CRDs) 1–3 from Mu0), and Man/GalNAc-4-SO4-Fc(Mu11) (deletion of the fibronectin type II repeat and CRDs 1–8 from Mu0) were prepared as described (5Fiete D.J. Beranek M.C. Baenziger J.U. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 2089-2093Crossref PubMed Scopus (154) Google Scholar). 3′-SO4-LewisX(3′-O-SO3Galβ1,4(Fucα1,3)GlcNAc) was from Calbiochem. S4GGnM-MCO, S3GGnM-MCO, and their BSA conjugates, S4GGnM-BSA and S3GGnM-BSA, were prepared as described (9Vandana O. Hindsgaul O. Baenziger J.U. Can. J. Chem. 1987; 65: 1645-1652Crossref Scopus (33) Google Scholar). The LHα subunit was supplied by the National Hormone and Pituitary Program (NIDDK, National Institutes of Health) and A. F. Parlow. Surface plasmon resonance (SPR) analyses were performed on an Amersham Pharmacia Biotech BIACORE 2000 instrument as described previously (8Roseman D.S. Baenziger J.U. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 9949-9954Crossref PubMed Scopus (68) Google Scholar). For studies using immobilized the Cys-rich domain, a predetermined amount of Man/GalNAc-4-SO4-Fc(Mu11) was allowed to bind to protein A (Pierce), which had been covalently attached to a CM5 sensor chip. The amount of Mu11 bound was monitored by SPR. No detectable dissociation of Mu11 from protein A was observed under the conditions of the assay. For inhibition studies the bovine LHα subunit (685 nm) was passed over the chip at a flow rate of 5 μl/min for 300 s in the presence of increasing concentrations of saccharide inhibitors. The amount of LHα bound at equilibrium was used to generate inhibition curves that were analyzed by nonlinear regression using PRISM software (version 2.0). Kivalues were calculated from the concentration of inhibitor that effected 50% inhibition. For glycoconjugate binding studies, differing concentrations of S4GGnM-BSA and S3GGnM-BSA were passed over immobilized Mu11 at a flow rate of 5 μl/min for 10 min. Dissociation was initiated at 10 min by elution with TBS buffer (20 mmTris·HCl, pH 7.4, 150 mm NaCl) + 0.005% (w/v) surfactant P20 or TBS buffer + 0.005% surfactant P20 containing 1 mmGalNAc-4-SO4. Binding of Mu11 to immobilized S4GGnM-BSA and S3GGnM-BSA was also monitored using SPR. Similar amounts of S4GGnM-BSA and S3GGnM-BSA were attached covalently to a BIACORE CM5 sensor chip through primary amine groups using the amine coupling kit provided by the manufacturer. The amount of S4GGnM-BSA and S3GGnM-BSA conjugated was determined from the increase in response units. Mu11 was passed over immobilized BSA conjugates at a flow rate of 5 μl/min for 10 min. The amount of Mu11 bound at equilibrium was used to generate saturation curves that were analyzed by nonlinear regression using PRISM software (version 2.0). Mole ratios were determined by dividing the change in response unit values obtained for immobilized or bound glycoproteins by their respective molecular weights. The molecular weights utilized were: LHα, 14,600; Mu11, 98,100; S4GGnM-BSA, 73,100; and S3GGnM-BSA, 73,100. The values calculated for S4GGnM-BSA and S3GGnM-BSA reflect the presence of 7 mol of sulfated trisaccharide conjugated/mol of BSA and are consistent with their mobility when examined by SDS-polyacrylamide gel electrophoresis (data not shown). 3′-SO4-LewisX and a glucose prepared from by acid Baenziger J.U. PubMed Scopus Google were with 9-aminopyrene-1,4,6-trisulfonic acid by as described A. PubMed Scopus Google Scholar). Binding was performed in a either 10 Mu11 or BSA in of TBS The of and in of TBS was allowed to for at were removed from of the and the amounts of and were by electrophoresis using on a and for as described by the manufacturer. The was used to the amount of because not demonstrate binding to Mu11 or of the of the sulfated was performed to the by 1998; PubMed Scopus Google Scholar). S4GGnM-BSA and S3GGnM-BSA were with acid to release their with in the were with by electrophoresis was performed using a in mm pH on a PubMed Scopus Google Scholar). The were and using and with Man/GalNAc-4-SO4-Fc(Mu10) was S4GGnM-BSA nm) in 150 of TBS buffer containing (w/v) and (w/v) bovine in the presence of increasing concentrations of S4GGnM-BSA or were by the of of and on as described D. Baenziger J.U. J. Biol. Chem. 1997; 272: 14629-14637Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar). We have characterized the affinity and of binding for ligands bearing of terminal β1,4-linked GalNAc-4-SO4 moieties SPR. The inhibition studies in were performed by the LHα subunit over Man/GalNAc-4-SO4-Fc(Mu11) bound to immobilized protein A in the presence of increasing amounts of monovalent inhibitors. S4GGnM-MCO, and values of and 16.2 μm, The Ki values obtained for GalNAc-4-SO4 and S4GGnM that recognition is at the terminal sulfated The Ki determined for S3GGnM is that obtained for for the monovalent trisaccharide of the sulfate at the C3 hydroxyl as compared with the C4 hydroxyl of the GalNAc with the binding site in the Cys-rich constants for monovalent and ligands sulfated at either the C3 or C4 hydroxyl of terminal GalNAc or for inhibition of LHα binding to immobilized Man/GalNAc-4-SO4-Fc(Mu11) on the inhibition of LHα binding to immobilized Man/GalNAc-4-SO4-Fc(Mu11) on the inhibition of LHα binding to immobilized Man/GalNAc-4-SO4-Fc(Mu11) on the inhibition of LHα binding to immobilized Man/GalNAc-4-SO4-Fc(Mu11) on the inhibition of binding to Man/GalNAc-4-SO4-Fc(Mu10) fibronectin type II domains and carbohydrate recognition domains 1–3 have been in the precipitation inhibition of binding to Man/GalNAc-4-SO4-Fc(Mu10) fibronectin type II domains and carbohydrate recognition domains 1–3 have been in the precipitation inhibition of LHα binding to immobilized Man/GalNAc-4-SO4-Fc(Mu11) on the inhibition of binding to Man/GalNAc-4-SO4-Fc(Mu10) fibronectin type II domains and carbohydrate recognition domains 1–3 have been in the precipitation for in a We also determined values for 3′-SO4-LewisX binding to Mu11 using equilibrium the conditions and the for equilibrium to be (data not shown). not bind to Mu11, and the Cys-rich domain (data not shown). bound to Mu11 with aKd of and of mol of of Cys-rich domain The by equilibrium is in with of obtained by inhibition studies on the BIACORE as described Furthermore, in with studies (8Roseman D.S. Baenziger J.U. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 9949-9954Crossref PubMed Scopus (68) Google and the (6Liu Y. Chirino A.J. Leteux C. Feizi T. Misulovin Z. Nussenzweig M.C. Bjorkman P. J. Exp. Med. 2000; 191: 1105-1115Crossref PubMed Scopus (113) Google Cys-rich domain a binding site for a sulfated We previously determined the dissociation for S4GGnM-BSA is 0.013 for Man/GalNAc-4-SO4-Fc(Mu0) and Man/GalNAc-4-SO4-Fc(Mu11) (5Fiete D.J. Beranek M.C. Baenziger J.U. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 2089-2093Crossref PubMed Scopus (154) Google Scholar). The utilized for these on precipitation of to or We determined inhibition constants for S4GGnM-BSA and S3GGnM-BSA using and Man/GalNAc-4-SO4-Fc(Mu10) was used because is than and is by than S4GGnM-BSA a Ki of 0.013 μm, S3GGnM-BSA a Ki of 0.170 This results in a 2000-fold change in the affinity for S4GGnM-BSA as compared with monovalent S4GGnM 25.8 and a 95-fold change in affinity for S3GGnM-BSA as compared with the monovalent S3GGnM 16.2 for S4GGnM is greater than for the Ki for S3GGnM-BSA is greater than the Ki for the Man/GalNAc-4-SO4 receptor displays significantly greater specificity for multivalent than for monovalent forms of the same The inhibition studies not to the molecular basis for the difference in specificity for monovalent and multivalent forms of the same We used to the of S4GGnM-BSA and S3GGnM-BSA binding to immobilized a concentration of the binding of S4GGnM-BSA rapidly with buffer of S4GGnM-BSA at s results in or The amount of S4GGnM-BSA bound a of mol of Mu11 or mol of Cys-rich domain. This is to a Cys-rich of which is a to the of on the of trisaccharides conjugated to the BSA and a binding site for terminal domain. this that the dissociation rate is a of multivalent a concentration of S4GGnM-BSA the amount of S4GGnM-BSA bound the binding of the of the of significant dissociation of the bound the amount of S4GGnM-BSA bound to Mu11 the same as was seen with for the of multivalency to the dissociation rate was obtained by of 1 mm GalNAc-4-SO4 the dissociation The S4GGnM-BSA was rapidly and that the equilibrium at GalNAc-4-SO4 binding sites is The dissociation rate in the presence of 1 mm GalNAc-4-SO4 is that the dissociation rate not be determined by SPR. S3GGnM-BSA was also bound by immobilized Mu11 The amount of S3GGnM-BSA bound was than the amount of S4GGnM-BSA bound at the same concentration concentrations in A and the amount of S3GGnM-BSA bound to Mu11 to increase with Furthermore, or dissociation of S3GGnM-BSA is observed when elution with buffer of S3GGnM-BSA is initiated at as was seen for S4GGnM-BSA, with S3GGnM-BSA are multivalent and Furthermore, bound S3GGnM-BSA is rapidly from Mu11 in the presence of 1 increased concentrations of S3GGnM-BSA, amounts of binding to obtained with S4GGnM-BSA can be (data not shown). S4GGnM-BSA S3GGnM-BSA at a significant rate from the immobilized Mu11, the results in and that at concentrations the association rate for S3GGnM-BSA is than for A difference in the of trisaccharide to BSA was as an for the by the of trisaccharide to BSA for acid the were with and by electrophoresis using a (data not shown). The of trisaccharide to BSA was for S4GGnM-BSA and for S3GGnM-BSA, which is in with the analyses performed at the of the seen for S4GGnM-BSA and S3GGnM-BSA binding to immobilized Mu11 reflect a significantly association rate for S3GGnM-BSA than for The multivalent of the binding of S4GGnM-BSA and S3GGnM-BSA to immobilized Mu11 and the of dissociation We used to the binding of Mu11 to concentrations of immobilized S4GGnM-BSA and Although the immobilized BSA conjugates are the Man/GalNAc-4-SO4-Fc(Mu11) is and can engage two terminal sulfated GalNAc The results of these analyses are in 5 and and in Mu11 equilibrium rapidly when binding to either immobilized S4GGnM-BSA or S3GGnM-BSA Mu11 bound to immobilized S4GGnM-BSA with a of and bound to immobilized S3GGnM-BSA with a of Mu11 bound to S4GGnM-BSA with of and bound to S3GGnM-BSA with a of and Mu11 to conjugates with a affinity under these is an difference in the amount of Mu11 bound at This is the and concentration of terminal sulfated saccharides are Mu11 to immobilized S4GGnM-BSA and S3GGnM-BSA with the a The equilibrium binding from the in 5 were used to generate saturation curves for Mu11 binding to immobilized S4GGnM-BSA and S3GGnM-BSA The results of regression analyses are in response of increasing concentrations of Mu11 to amounts of immobilized S3GGnM-BSA and S4GGnM-BSA was monitored by for for amount bound at equilibrium for concentration in 5 was used to generate the curves in The were determined by nonlinear regression for in a The amount bound at equilibrium for concentration in 5 was used to generate the curves in The were determined by nonlinear regression Our analyses demonstrate that inhibition constants obtained with monovalent ligands do not the properties of multivalent forms of the same ligands. This the basis for the difference in specificity by the Man/GalNAc-4-SO4 receptor for multivalent as compared with monovalent ligands. The clearance studies we performed in the (1Baenziger J.U. Kumar S. Brodbeck R.M. Smith P.L. Beranek M.C. Proc. Natl. Acad. Sci. U. S. A. 1992; 89: 334-338Crossref PubMed Scopus (160) Google as well as analyses with the isolated hepatic endothelial cells (2Fiete D. Srivastava V. Hindsgaul O. Baenziger J.U. Cell. 1991; 67: 1103-1110Abstract Full Text PDF PubMed Scopus (264) Google and the purified Man/GalNAc-4-SO4 receptor D. Baenziger J.U. J. Biol. Chem. 1997; 272: 14629-14637Abstract Full Text Full Text PDF PubMed Scopus (60) Google indicated that this receptor displays specificity for the of the sulfate on terminal β1,4-linked GalNAc in the of the The C. Chai W. Loveless R.W. Yuen C.-T. Uhlin-Hansen L. Combarnous Y. Jankovic M. Maric S.C. Misulovin Z. Nussenzweig M.C. Feizi T. J. Exp. Med. 2000; 191: 1117-1126Crossref PubMed Scopus (149) Google that monovalent saccharides with a sulfate located at the C3 hydroxyl of Gal values to of monovalent structures with the sulfate located at the C4 hydroxyl of Gal or GalNAc to these The studies we have demonstrate that the Man/GalNAc-4-SO4 receptor displays greater specificity for multivalent ligands than be on the basis of binding constants obtained for monovalent forms of the same ligands. Cys-rich domain is to engage a terminal sulfated In with the studies of Leteux C. Chai W. Loveless R.W. Yuen C.-T. Uhlin-Hansen L. Combarnous Y. Jankovic M. Maric S.C. Misulovin Z. Nussenzweig M.C. Feizi T. J. Exp. Med. 2000; 191: 1117-1126Crossref PubMed Scopus (149) Google and (6Liu Y. Chirino A.J. Leteux C. Feizi T. Misulovin Z. Nussenzweig M.C. Bjorkman P. J. Exp. Med. 2000; 191: 1105-1115Crossref PubMed Scopus (113) Google Scholar, Y. Misulovin Z. Bjorkman J. Biol. PubMed Scopus Google monovalent forms of the trisaccharide sulfated at either the C3 or C4 hydroxyl of the terminal GalNAc are bound with affinities of 16.2 and 25.8 μm, respectively. can account for the dissociation constants of 0.170 and 0.013 obtained for S3GGnM-BSA and S4GGnM-BSA, have previously observed greater specificity on the of for ligands as compared with their monovalent J.U. Y. J. Biol. Chem. Full Text PDF PubMed Google Scholar, J.U. D. Cell. Full Text PDF PubMed Scopus (154) Google Scholar, Chem. Scopus Google Scholar, P. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar, L. D. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar, J. M. C. L. D. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: PubMed Scopus Google Scholar, J. Chem. Scopus Google Scholar, S. J. Biol. Chem. 2000; Full Text Full Text PDF PubMed Scopus Google Scholar). The specificity for multivalent ligands been to a for J.U. Y. J. Biol. Chem. Full Text PDF PubMed Google Scholar, J.U. D. Cell. Full Text PDF PubMed Scopus (154) Google Scholar, Chem. Scopus Google Scholar, P. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google and interactions L. D. Proc. Natl. Acad. Sci. U. S. A. PubMed Scopus Google Scholar, J. M. C. L. D. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: PubMed Scopus Google and in the of in the affinities monovalent forms J. Chem. Scopus Google Scholar). of a in which in affinity of monovalent ligands are in the is that the affinities obtained for Mu11 binding to immobilized S4GGnM-BSA and S3GGnM-BSA that the at saturation be the This is not the because Mu11 to immobilized S4GGnM-BSA and S3GGnM-BSA with the same affinity with an difference in The seen in is the trisaccharide S3GGnM exists in two distinct of which is favorable for binding The structures of the Cys-rich domain binding and 3′-SO4-LewisX display significant in the of the that or of the oligosaccharides a conformational change when binding to the Cys-rich domain Y. Misulovin Z. Bjorkman J. Biol. PubMed Scopus Google Scholar). on the may an greater change in to of requires the of two terminal moieties by the a of the S3GGnM is in a form favorable for binding at in and of the S4GGnM is in a favorable form for the effective concentration of S3GGnM-BSA to be a fraction of that of when binding does to the favorable form of have the same properties as the binding to the two have the same in the of conformational M. Chem. 1998; PubMed Google as the of from a difference in the of conformations and are the basis for the difference in values obtained for S4GGnM-BSA and S3GGnM-BSA and S4GGnM-BSA bind to immobilized Mu11, this difference is as a association rate for S3GGnM-BSA as compared with S4GGnM-BSA a of terminal sulfated saccharides are the multivalent results in a dissociation rate for S3GGnM-BSA and S4GGnM-BSA 7 a S3GGnM-BSA the same of binding as S4GGnM-BSA when examined on the at binding sites is because S3GGnM-BSA and S4GGnM-BSA from the immobilized Mu11 in the presence of 1 at a rate that is to and 7 Rapid at binding sites in conjunction with conformations that are favorable and for binding may account for the Ki values obtained for monovalent forms of these sulfated The of binding to immobilized Mu11 and the values obtained for S4GGnM-BSA and S3GGnM-BSA the seen in (2Fiete D. Srivastava V. Hindsgaul O. Baenziger J.U. Cell. 1991; 67: 1103-1110Abstract Full Text PDF PubMed Scopus (264) Google Scholar). S4GGnM-BSA is rapidly removed from the blood S3GGnM-BSA is removed the 12-fold difference in clearance rate well with the difference in Furthermore, S4GGnM-BSA not S3GGnM-BSA is bound and by isolated hepatic endothelial cells (2Fiete D. Srivastava V. Hindsgaul O. Baenziger J.U. Cell. 1991; 67: 1103-1110Abstract Full Text PDF PubMed Scopus (264) Google Scholar). the form of the Man/GalNAc-4-SO4 receptor in hepatic endothelial cells exists as a (8Roseman D.S. Baenziger J.U. Proc. Natl. Acad. Sci. U. S. A. 2000; 97: 9949-9954Crossref PubMed Scopus (68) Google binding two terminal is not to produce a to mediate In the with a greater of terminal by dimeric GalNAc-4-SO4 is a to the rate of receptor a ligands terminating with Gal or GalNAc sulfated at the C3 hydroxyl are not to ligands for the vivo. forms of the Man/GalNAc-4-SO4 receptor have been reported in the circulation and are to as a of L. S. J. Biol. Chem. 1998; Full Text Full Text PDF PubMed Scopus Google Scholar). These forms of the GalNAc-4-SO4 receptor not be to bind terminal or dimeric or are in The amount of or that be be at least than the forms of the Man/GalNAc-4-SO4 receptor in serum as dimeric or molecules to be Our studies demonstrate that the binding site of the Cys-rich domain of the Man/GalNAc-4-SO4 receptor can accommodate a of sulfated as monovalent displays specificity when two or terminal sulfated GalNAc or Gal this specificity is through in conformational is and may to in which multivalent ligands are recognized by with greater specificity than the same monovalent ligands. The affinity and specificity of the Man/GalNAc-4-SO4 receptor for oligosaccharides terminating with β1,4-linked GalNAc-4-SO4 are for the of LH in the circulation the the The to ligands monovalent or multivalent that the clearance of LH be sulfated ligands are in the multivalent forms of S3GGnM are from binding multivalent forms of S4GGnM are not of such ligands in the presence of dimeric Cys-rich of oligosaccharides terminating with GalNAc-4-SO4 and in their structures that have a major impact on to the binding site on the Cys-rich domain. This a novel to the specificity of carbohydrate for multivalent saccharide structures in vivo. We Baenziger for

References

23